Elevated serum levels of APRIL, but not BAFF, in patients with atopic dermatitis

Experimental Dermatology

Volumn 17, Issue 3, 2008, Pages 197-202

  Matsushita, Takashi ^a   Fujimoto, Manabu ^a   Echigo, Takeshi ^a   Matsushita, Yukiyo ^a   Shimada, Yuka ^a   Hasegawa, Minoru ^a   Takehara, Kazuhiko ^a   Sato, Shinichi ^b  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

APRIL; Atopic dermatitis; BAFF; Eosinophil; Immunoglobulin E

Indexed keywords

ANTIHISTAMINIC AGENT; APRIL PROTEIN; B CELL ACTIVATING FACTOR; IMMUNOGLOBULIN E; STEROID; TUMOR NECROSIS FACTOR;

ADOLESCENT; ADULT; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE REDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL COUNT; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; PATHOGENESIS; PROTEIN BLOOD LEVEL; PSORIASIS VULGARIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; ANTI-ALLERGIC AGENTS; B-CELL ACTIVATING FACTOR; DERMATITIS, ATOPIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; EOSINOPHILS; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN E; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PSORIASIS; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 39049128735     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2007.00642.x     Document Type: Article

References (49)

1. Hanifin J M, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980: 92 (Suppl.): 44-47.
2. Hanifin J M. Atopic dermatitis. J Am Acad Dermatol 1982: 6: 1-13.
3. Leung D Y. Atopic dermatitis: New insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000: 105: 860-876.
4. Leung D Y. Pathogenesis of atopic dermatitis. J Allergy Clin Immunol 1999: 104: S99-S108.
5. Van der Heijden F L, Wierenga E A, Bos J D, Kapsenberg M L. High frequency of IL-4-producing CD4+ allergen specific T lymphocytes in atopic dermatitis lesional skin. J Invest Dermatol 1991: 97: 389-394.
6. Hamid Q, Boguniewicz M, Leung D Y. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 1994: 94: 870-876.
7. Hamid Q, Naseer T, Minshall E M, Song Y L, Boguniewicz M, Leung D Y. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol 1996: 98: 225-231.
8. Bos J D, Wierenga E A, Sillevis Smitt J H, van der Heijden F L, Kapsenberg M L. Immune dysregulation in atopic eczema. Arch Dermatol 1992: 128: 1509-1512.
9. Grewe M, Gyufko K, Schopf E, Krutmann J. Lesional expression of interferon-gamma in atopic eczema. Lancet 1994: 343: 25-26.
10. Tsicopoulos A, Hamid Q, Haczku A et al. Kinetics of cell infiltration and cytokine messenger RNA expression after intradermal challenge with allergen and tuberculin in the same atopic individuals. J Allergy Clin Immunol 1994: 94: 764-772.
11. Mackay F, Browning J L. BAFF: A fundamental survival factor for B cells. Nat Rev Immunol 2002: 2: 465-475.
12. Moore P A, Belvedere O, Orr A et al. BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999: 285: 260-263.
13. Schneider P, MacKay F, Steiner V et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999: 189: 1747-1756.
14. Craxton A, Magaletti D, Ryan E J, Clark E A. Macrophage - and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 2003: 101: 4464-4471.
15. Litinskiy M B, Nardelli B, Hilbert D M et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002: 3: 822-829.
16. Shu H B, Hu W H, Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol 1999: 65: 680-683.
17. Yu G, Boone T, Delaney J et al. APRIL and TALL-I and receptors BCMA and TACI: System for regulating humoral immunity. Nat Immunol 2000: 1: 252-256.
18. O'Connor B P, Raman V S, Erickson L D et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004: 199: 91-98.
19. Thompson J S, Bixler S A, Qian F et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001: 293: 2108-2111.
20. Ng L G, Sutherland A P, Newton R et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004: 173: 807-817.
21. Ye Q, Wang L, Wells A D et al. BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses. Eur J Immunol 2004: 34: 2750-2759.
22. Ingold K, Zumsteg A, Tardivel A et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005: 201: 1375-1383.
23. Hendriks J, Planelles L, de Jong-Odding J et al. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ 2005: 12: 637-648.
24. Sakurai D, Hase H, Kanno Y, Kojima H, Okumura K, Kobata T. TACI regulates IgA production by APRIL in collaboration with HSPG. Blood 2007: 109: 2961-2967.
25. Thien M, Phan T G, Gardam S et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004: 20: 785-798.
26. Marsters S A, Yan M, Pitti R M, Haas P E, Dixit V M, Ashkenazi A. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 2000: 10: 785-788.
27. Huard B, Arlettaz L, Ambrose C et al. BAFF production by antigen-presenting cells provides T cell co-stimulation. Int Immunol 2004: 16: 467-475.
28. Huard B, Schneider P, Mauri D, Tschopp J, French L E. T cell costimulation by the TNF ligand BAFF. J Immunol 2001: 167: 6225-6231.
29. Koyama T, Tsukamoto H, Miyagi Y et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005: 64: 1065-1067.
30. Jonsson M V, Szodoray P, Jellestad S, Jonsson R, Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. J Clin Immunol 2005: 25: 189-201.
31. Cheema G S, Roschke V, Hilbert D M, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001: 44: 1313-1319.
32. Zhang J, Roschke V, Baker K P et al. Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001: 166: 6-10.
33. Groom J, Kalled S L, Cutler A H et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002: 109: 59-68.
34. Stohl W, Metyas S, Tan S M et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthritis Rheum 2003: 48: 3475-3486.
35. Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006: 54: 192-201.
36. Migita K, Abiru S, Maeda Y et al. Elevated serum BAFF levels in patients with autoimmune hepatitis. Hum Immunol 2007: 68: 586-591.
37. Asashima N, Fujimoto M, Watanabe R et al. Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris. Br J Dermatol 2006: 155: 330-336.
38. Watanabe R, Fujimoto M, Yazawa N et al. Increased serum levels of a proliferation-inducing ligand in patients with bullous pemphigoid. J Dermatol Sci 2007: 46: 53-60.
39. Matsushita T, Hasegawa M, Matsushita Y et al. Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases. Exp Dermatol 2007: 16: 87-93.
40. Gross J A, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000: 404: 995-999.
41. Kayagaki N, Yan M, Seshasayee D et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 2002: 17: 515-524.
42. Gross J A, Dillon S R, Mudri S et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity 2001: 15: 289-302.
43. Seyler T M, Park Y W, Takemura S et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005: 115: 3083-3092.
44. Kang J S, Yoon Y D, Ahn J H et al. B cell-activating factor is a novel diagnosis parameter for asthma. Int Arch Allergy Immunol 2006: 141: 181-188.
45. Sutherland A P, Ng L G, Fletcher C A et al. BAFF augments certain Th1-associated inflammatory responses. J Immunol 2005: 174: 5537-5544.
46. Rajka G, Langeland T. Grading of severity of atopic dermatitis. Acta Derm Venerol 1989: 144: 13-14.
47. Tan E M, Cohen A S, Fries J F et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982: 25: 1271-1277.
48. Xu W, He B, Chiu A et al. Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat Immunol 2007: 8: 294-303.
49. Kato A, Truong-Tran A Q, Scott A L, Matsumoto K, Schleimer R P. Airway epithelial cells produce B cell-activating factor of TNF family by an IFN-beta-dependent mechanism. J Immunol 2006: 177: 7164-7172.